Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Clin Drug Investig.

Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C

doi: 10.1007/s40261-017-0611-3.

SPECIAL REPORT

Further Publications

Adjuvant Targeted Therapy in BRAF-Mutated Melanoma

Lung, Respiratory and Thoracic Cancer

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib vs Comparator EGFR-TKI as First-Line Treatment in Patients with EGFR Mutated Advanced NSCLC

Clin Cancer Res.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste JF, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden SP, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam S

doi: 10.1158/1078-0432.CCR-19-1126.

Gastrointestinal Cancer

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy

Eur Rev Med Pharmacol Sci.

De Dosso S, Nucifora M, Sahnane N, Epistolio S, Riveiro ME, Bertolini V, Bucci E, Boldorini R, Fregua S, Frattini M, Saletti P

doi: 10.26355/eurrev_202003_20664.

Radio-Oncology

Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis

JAMA Oncol.

Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR

doi: 10.1001/

Lung, Respiratory and Thoracic Cancer

Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC

J Thorac Oncol.

Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M

doi: 10.1016/j.jtho.2018.02.014.

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer

Clin Cancer Res.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y

doi: 10.1158/1078-0432.CCR-18-3325.

Lung, Respiratory and Thoracic Cancer

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Eur J Cancer

Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oizumi S, Okamoto I

doi: 10.1016/j.ejca.2021.02.019

Lung, Respiratory and Thoracic Cancer

Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations

J Thorac Oncol.

Passaro A, Mok T, Peters S, Popat S, Ahn MJ, De Marinis F

doi: 10.1016/j.jtho.2020.12.002.

Related content

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

Adjuvant Targeted Therapy in BRAF-Mutated Melanoma

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib vs Comparator EGFR-TKI as First-Line Treatment in Patients with EGFR Mutated Advanced NSCLC

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy

Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis

Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer

Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial

Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations